menatetrenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists 1685 863-61-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • menatetrenone
  • Menaquinone 4
  • Vitamin MK 4
  • vitamin k2
  • Molecular weight: 444.66
  • Formula: C31H40O2
  • CLOGP: 10.24
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 34.14
  • ALOGS: -5.96
  • ROTB: 11

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0.23 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 62
kinase-selectivity-class AXL,BRAF,CDK4,EIF2AK3,GRK2,MAP2K6,STK33,TEK,TTK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 41.63 26.86 16 1521 26580 90600330
Hepatic function abnormal 39.27 26.86 18 1519 46270 90580640
Disseminated intravascular coagulation 30.31 26.86 12 1525 21526 90605384
Platelet count decreased 29.91 26.86 22 1515 136947 90489963

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral haemorrhage 74.41 29.12 31 1155 38935 42581214
Cerebral infarction 37.58 29.12 18 1168 31151 42588998
Hepatic function abnormal 36.95 29.12 21 1165 51546 42568603
Thalamus haemorrhage 30.96 29.12 7 1179 1112 42619037

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral haemorrhage 88.94 23.53 40 2805 64928 110521526
Cerebral infarction 77.63 23.53 34 2811 51804 110534650
Hepatic function abnormal 71.15 23.53 38 2807 89257 110497197
Disseminated intravascular coagulation 48.88 23.53 23 2822 41263 110545191
Platelet count decreased 44.43 23.53 41 2804 230402 110356052
Brain herniation 39.82 23.53 13 2832 8850 110577604
Thalamus haemorrhage 37.71 23.53 9 2836 1955 110584499
Altered state of consciousness 36.22 23.53 21 2824 57605 110528849
Embolic stroke 32.03 23.53 11 2834 8732 110577722
Pneumonia 31.09 23.53 69 2776 876645 109709809
Upper respiratory tract inflammation 30.57 23.53 9 2836 4362 110582092
Renal impairment 29.64 23.53 30 2815 188415 110398039
Serum ferritin increased 28.77 23.53 11 2834 11836 110574618
Pneumonia aspiration 27.32 23.53 20 2825 81213 110505241
Brain oedema 26.90 23.53 14 2831 31084 110555370
Pyrexia 24.60 23.53 64 2781 898201 109688253
Putamen haemorrhage 24.40 23.53 5 2840 540 110585914

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M05BX08 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Other drugs affecting bone structure and mineralization
MeSH PA D003029 Coagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D006490 Hemostatics
MeSH PA D000933 Antifibrinolytic Agents
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
CHEBI has role CHEBI:22586 antioxidant
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

M05BX Other drugs affecting bone structure and mineralization 8 drugs
aluminium chlorohydrateburosumabcolecalciferoldenosumabipriflavoneromosozumabstrontium ranelatevosoritide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hemorrhagic disease of the newborn due to vitamin K deficiency indication 12546009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-synuclein Transporter IC50 4.82 CHEMBL
Cruzipain Enzyme IC50 4.74 CHEMBL

External reference:

IDSource
D00100 KEGG_DRUG
C0065936 UMLSCUI
CHEBI:16374 CHEBI
1L3 PDB_CHEM_ID
CHEMBL259223 ChEMBL_ID
CHEMBL5314971 ChEMBL_ID
DB12148 DRUGBANK_ID
C030814 MESH_SUPPLEMENTAL_RECORD_UI
3292 INN_ID
27Y876D139 UNII
5282367 PUBCHEM_CID
DB14936 DRUGBANK_ID
29495 RXNORM
337527 MMSL
35482 MMSL
37263 MMSL
d09345 MMSL
012756 NDDF
013766 NDDF
22606007 SNOMEDCT_US
712684001 SNOMEDCT_US
D024482 MESH_DESCRIPTOR_UI
2771 IUPHAR_LIGAND_ID

Pharmaceutical products:

None